RxDoctor Payments Data

Juan Ochoa, MD

Neurology · Mobile, ALNPI 1013986041

Payments from drug & device makers

$25,013in general payments, 2019–2025

Across 391 payments — averaging $63.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Cadwell Industries, Inc$15K
  • UCB, Inc.$2K
  • Medtronic$1K
  • Eisai Inc.$682
  • Sunovion Pharmaceuticals Inc.$650
  • Jazz Pharmaceuticals Inc.$574
  • plus $5K from 48 others

What the payments were for

  • Speaking & faculty fees$2,0448%
  • Travel & lodging$9084%
  • Food & beverage$9,14137%
  • Charitable contribution$12,91952%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$25,013 in reported general payments places this provider in the 70th percentile of 255 neurology providers in Alabama.

See all neurology providers in Alabama

Medicare billing

Part B allowed, 2024
$31,992
Medicare patients
148
Services billed
280

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AptiomEslicarbazepine Acetate212$621,531
Vigabatrin29$459,860
XcopriCenobamate130$165,109
Lacosamide194$49,046
EpidiolexCannabidiol (Cbd)13$47,265
Sirolimus12$35,926
FycompaPerampanel15$25,176
Clobazam135$13,129
Lamotrigine ErLamotrigine13$8,849
Zonisamide163$7,440
Oxcarbazepine81$6,386
Levetiracetam152$5,697
Lamotrigine217$4,999
Felbamate12$2,911
Gabapentin102$1,670

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sunovion Pharmaceuticals Inc.Aptiom$650$621,531212 claims
SK Life Science, Inc.Xcopri$497$165,109130 claims
Eisai Inc.Fycompa$682$25,17615 claims
Upsher-smith Laboratories LLCTopiramate$55$88474 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 255 neurology providers in Alabama.

Other neurology in Mobile

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →